Eli Lilly stock: Leerink raises Eli Lilly stock target from USD 1,309.00 to USD 1,316.00

Published on 10/23/2026 at 15:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Earnings are due October 29, 2026 at 10:00 a.m. EDT. Eli Lilly stock costs EUR 1,148.90 on October 23, 2026, down 2.19 percent versus Xetra close.

Leerink raises target to USD 1,316.00

Leerink raised its Eli Lilly target from USD 1,309.00 to USD 1,316.00 on October 21, 2026.
Second-quarter 2026 revenue reached USD 22.97 billion, up 47.70 percent year over year.
Eli Lilly stock costs EUR 1,148.90 at Lang & Schwarz on October 23, 2026 at 3:39 p.m. CEST, 2.19 percent below the Xetra close.
The third-quarter 2026 earnings call is scheduled for October 29, 2026.

Extreme Makroaufnahme eines hochpolierten Edelstahlflanschs mit O-Ring-Dichtung einer Vakuumkammer auf schwarzem Hintergrund — Lam Research US5324571083 Makro polierter Vakuumkammer Flansch mit O Ring Dichtung auf schwarzem Hintergrund, Illustration mit AI erstellt.

Eli Lilly and Co. (US5324571083) drew a higher target from Leerink, which raised its price target from USD 1,309.00 to USD 1,316.00 on October 21, 2026, according to Markets Insider. At Lang & Schwarz, the stock was trading at EUR 1,148.90 on October 23, 2026 at 3:39 p.m. CEST, down 2.19 percent versus the Xetra close of October 22, 2026 (EUR 1,174.60).

Revenue growth sets the backdrop

Lilly reported USD 22.97 billion in second-quarter 2026 revenue, up 47.70 percent from the same quarter a year earlier. Revenue also exceeded the USD 20.82 billion consensus figure by USD 2.15 billion, according to MarketBeat. The comparison gives the analyst target a more demanding earnings backdrop ahead of the next report.

Stock stays near its yearly high

The NYSE quote was USD 1,283.15 on October 23, 2026 at 9:53 a.m. EDT. Lilly's 52-week range was USD 809.63 to USD 1,321.21, placing the stock 2.88 percent below its high and 58.48 percent above its low. The quoted market capitalization was USD 1.2 trillion, while the price-to-earnings ratio stood at 43.05.

October 29 brings the next test

Lilly's investor-relations calendar lists the third-quarter 2026 earnings call for October 29, 2026 at 10:00 a.m. EDT. The same calendar names an Innovation Day for December 7, 2026, giving investors two scheduled company dates beyond the recent target revision. Leerink's USD 1,316.00 target lies 2.56 percent above the USD 1,283.15 NYSE quote.

Target leaves limited room above the quote

The target revision is modest in absolute terms, rising USD 7.00 from USD 1,309.00. Against the current US-dollar quote, the new target implies 2.56 percent upside, while the euro quotation sits below its October 22 Xetra close. This leaves the October 29 report as the next dated test for the revenue trajectory and valuation.

Price and scheduled dates

The price picture combines a USD 1.2 trillion market capitalization with a 43.05 price-to-earnings ratio and a 2.88 percent distance from the 52-week high. The scheduled earnings call on October 29, 2026 supplies the next concrete date for investors following the target revision.

Trading position

Lilly's euro quotation remained below the prior Xetra session close during the regular European session, while the US listing was also below its previous USD close. The stock's position near the 52-week high keeps the USD 1,316.00 target within a narrow 2.56 percent distance of the latest US quote.

The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.